Dr Lal Pathlabs Ltd News

Healthcare stocks shine in weak market; Metropolis, Thyrocare jump upto 14%

Metropolis Healthcare share hit a 52-week high of ₹574.45, surging 14 per cent in trade. Thyrocare soared 12 per cent to ₹526.10, while Vijaya Diagnostic Centre gained 7 per cent to ₹1,298.45.

Dr Lal PathLabs hits 20% upper band on strong Q4; brokerages stay positive

Dr. Lal PathLabs recorded a 16.6 per cent Y-o-Y rise in revenue from operations to ₹702 crore in Q4 FY26 from ₹659.8 crore in the year-ago period

Dr Lal PathLabs Q4FY26 results: Net profit falls 15%; revenue rises 16.6%

Diagnostics firm reports profit decline due to prior-year tax benefit, while revenue growth remains strong on higher sample volumes and improved test mix

Dr Lal Path Labs Q4 FY26 results: Profit down 15.5%, revenue up 16.6%

Consolidated net profit fell to 1.31 billion rupees ($13.8 million) in the quarter ended March, from 1.55 billion rupees a year earlier

Diagnostics stocks favoured on Q4 optimism amid strong volume growth

Sector to outshine healthcare peers as higher volumes, steady realisations will boost revenue and profit, say analysts

Dr Lal PathLabs Q3 net profit falls 6.4% on new labour code impact

Diagnostics major reports a one-time charge linked to new labour codes even as revenue rose over 10% on higher sample volumes and network expansion

Dr Lal Path Labs Q3 results: PAT dips to ₹90.5 cr on labour code changes

The ​country's largest diagnostics firm by revenue took up a one-time charge worth ₹30.1 crore linked to India's new labour codes

HDFC Sec turns bullish on Dr Lal PathLabs; upgrades to 'Buy'; raises target

Dr Lal PathLabs is focusing on innovation, including new wellness packages and high-end, super-speciality tests, with a focus on capturing prescription shares